Compare ADMA Biologics Inc (ADMA) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs SkyWest Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while SkyWest Inc trades at $96.55 (market cap $3.88B). The key difference: SkyWest Inc is the larger of the two by market cap, and SkyWest Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SKYW | |
|---|---|---|
Market Cap | $2.13B | $3.88B |
Sector | Health | Technology |
52-Week High | $20.38 | $123.72 |
52-Week Low | $7.60 | $78.40 |
Enterprise Value | $2.20B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SkyWest (SKYW) trades at $98.75, up 1.93% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 9.47 and P/S of 0.99, while maintaining strong profitability with 10.42% net margin and 16.5% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains stable revenue around $4.1B with consistent cash flow generation from operations exceeding $900M annually.
The outlook remains positive with 56% analyst buy ratings and $109.33 consensus price target suggesting 11% upside. Key risks include rising fuel costs impacting airline profitability and negative net cash flow trends. The upcoming Q2 2026 earnings call on July 23 will be crucial for confirming growth trajectory amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
